Tonix Pharmaceuticals Holding Corp. (TNXP) — Financial statements
Income statement, balance sheet, and cash flow for Tonix Pharmaceuticals Holding Corp. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 13↑29.8% | 10↑29.9% | 8 | 0.00 | 0.00 | |
| Cost of Revenue | 9↑10.3% | 8↑63.8% | 5 | 0.00 | 0.00 | |
| Gross Profit | 5↑95.0% | 2↓23.1% | 3 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 44↑10.0% | 40↓53.3% | 87↑5.8% | 82↑18.9% | 69 | |
| General & Administrative Expenses | 0.00↓100.0% | 3↓90.2% | 35↑15.0% | 30↑28.7% | 23 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 37 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 86↑113.9% | 40↑15.4% | 35↑15.0% | 30↑28.7% | 23 | |
| Other Expenses | 0.00↓100.0% | 58 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 130↓6.3% | 139↑14.5% | 121↑8.3% | 112↑21.4% | 92 | |
| Total Costs & Expenses | 139↓5.4% | 147↑16.4% | 126↑12.5% | 112↑21.4% | 92 | |
| Operating Results | ||||||
| Operating Income | -126↑8.0% | -137↓15.5% | -118↓5.6% | -112↓21.4% | -92 | |
| Depreciation & Amortization | 2↓43.7% | 3↓20.3% | 4↑242.5% | 1↑2406.0% | 0.05 | |
| EBITDA | -124↓66.5% | -74↑34.9% | -114↓2.9% | -111↓20.1% | -92 | |
| EBIT | -126↓61.7% | -78↑34.3% | -118↓5.6% | -112↓21.4% | -92 | |
| Interest & Other Income | ||||||
| Net Interest Income | 4 | 0.00 | 0.00↓100.0% | 2↑7392.0% | 0.03 | |
| Interest Income | 4 | 0.00 | 0.00↓100.0% | 2↑7392.0% | 0.03 | |
| Interest Expense | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -59 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 2↓74.8% | 7↑287.0% | 2↓8.1% | 2↑7392.0% | 0.03 | |
| Income Before Tax | -124↑4.6% | -130↓11.5% | -117↓5.8% | -110↓19.4% | -92 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -124↑4.6% | -130↓11.5% | -117↓5.8% | -110↓19.4% | -92 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -124↑4.6% | -130↓11.5% | -117↓5.8% | -110↓19.4% | -92 | |
| Bottom-Line Net Income | -124↑4.6% | -130↓11.5% | -117↑0.2% | -117↓26.6% | -92 | |
| EPS (Basic) | -14.57↑91.7% | -176.60↑97.2% | -6,368.84↓684.6% | -811.68↑99.5% | -163,968.00 | |
| EPS (Diluted) | -14.57↑91.7% | -176.60↑97.2% | -6,368.84↓684.6% | -811.68↑99.5% | -163,968.00 | |
| Weighted Average Shares | 9↑276.0% | 2↑23.6% | 2↓40.3% | 3↑545981.9% | 0.00 | |
| Weighted Average Diluted Shares | 9↑276.0% | 2↑23.6% | 2↓40.3% | 3↑545981.9% | 0.00 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.